| Frazier Mountain Community Health Center | |
|
704 Lebec Rd Lebec CA 93243 | |
| (661) 248-5250 | |
| (661) 248-5279 |
| Full Name | Frazier Mountain Community Health Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 704 Lebec Rd, Lebec, California |
| Authorized Official Name and Position | Olga Meave (CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 6616353050 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Frazier Mountain Community Health Center Po Box 1559 Bakersfield CA 93302-1559 Ph: (661) 635-3050 | Frazier Mountain Community Health Center 704 Lebec Rd Lebec CA 93243 Ph: (661) 248-5250 |
| NPI Number | 1457353831 |
|---|---|
| Provider Enumeration Date | 08/15/2005 |
| Last Update Date | 09/07/2023 |
| Medicare PECOS PAC ID | 3870407505 |
|---|---|
| Medicare Enrollment ID | O20100612000068 |
News Archive
In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Ohio University mathematics professor Winfried Just's new book COVID-19: Unmasked - The News, the Science, and Common Sense tackles the persistent and sometimes controversial questions people have been asking about COVID-19 in a new, conversational way.
The National Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia Mason (BRI) a $1.9 million grant to find marks in the human genome which can explain why some white blood cells cause damage to the spinal cord and brain in multiple sclerosis (MS).
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457353831 | NPI | - | NPPES |
| 12040F | Medicaid | CA | |
| ZZZ65152Z | Other | CA | BLUE SHIELD PIN |
| HAP12040F | Other | CA | FAMILY PACT |
| BCP12040F | Other | CA | CDP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 120000199 (California) | Primary |
News Archive
In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.
Ohio University mathematics professor Winfried Just's new book COVID-19: Unmasked - The News, the Science, and Common Sense tackles the persistent and sometimes controversial questions people have been asking about COVID-19 in a new, conversational way.
The National Institutes of Health (NIH) awarded Benaroya Research Institute at Virginia Mason (BRI) a $1.9 million grant to find marks in the human genome which can explain why some white blood cells cause damage to the spinal cord and brain in multiple sclerosis (MS).
› Verified 6 days ago